Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The temporary NIH transition announcement about using “Super Intelligence” alongside “Artificial Intelligence” no longer appears at the top of the page.
    Difference
    1%
    Check dated 2026-11-08T14:48:01.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-01T15:46:41.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    An NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the unavailable study record, with links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T15:48:23.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-18T22:21:36.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T22:23:18.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content for NCT02708641, indicating access is blocked. This reflects an access/error condition rather than a content update.
    Difference
    18%
    Check dated 2026-09-20T22:40:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.